BTTX vs. ACORQ, MOTS, SINT, ALLR, NVTA, ADTX, AMPE, APVO, SMFL, and ATHX
Should you be buying Better Therapeutics stock or one of its competitors? The main competitors of Better Therapeutics include Acorda Therapeutics (ACORQ), Motus GI (MOTS), Sintx Technologies (SINT), Allarity Therapeutics (ALLR), Invitae (NVTA), Aditxt (ADTX), Ampio Pharmaceuticals (AMPE), Aptevo Therapeutics (APVO), Smart for Life (SMFL), and Athersys (ATHX). These companies are all part of the "medical" sector.
Better Therapeutics (NASDAQ:BTTX) and Acorda Therapeutics (NASDAQ:ACORQ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends, risk and community ranking.
Better Therapeutics has a net margin of 0.00% compared to Acorda Therapeutics' net margin of -214.95%. Better Therapeutics' return on equity of 0.00% beat Acorda Therapeutics' return on equity.
Better Therapeutics received 5 more outperform votes than Acorda Therapeutics when rated by MarketBeat users.
Better Therapeutics presently has a consensus target price of $6.00, suggesting a potential upside of 57,042.86%. Given Better Therapeutics' higher probable upside, equities research analysts clearly believe Better Therapeutics is more favorable than Acorda Therapeutics.
Better Therapeutics has higher earnings, but lower revenue than Acorda Therapeutics. Better Therapeutics is trading at a lower price-to-earnings ratio than Acorda Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Better Therapeutics' average media sentiment score of 0.00 equaled Acorda Therapeutics'average media sentiment score.
Better Therapeutics has a beta of 2.13, meaning that its stock price is 113% more volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500.
34.0% of Better Therapeutics shares are held by institutional investors. Comparatively, 12.7% of Acorda Therapeutics shares are held by institutional investors. 51.4% of Better Therapeutics shares are held by company insiders. Comparatively, 2.6% of Acorda Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Better Therapeutics beats Acorda Therapeutics on 10 of the 13 factors compared between the two stocks.
Get Better Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BTTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BTTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Better Therapeutics Competitors List
Related Companies and Tools
